ArticlePlant foods for human nutrition (Dordrecht, Netherlands)2025
Phytochemical Analysis of Triphala Extract, In Vitro and In Silico Evaluation of Pancreatic Lipase Inhibition for Obesity Management.
Article in Plant foods for human nutrition (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pancreatic lipase (PL) inhibition is a prominent pharmacological strategy for managing obesity, as it reduces the hydrolysis of dietary triglycerides (TAG) into free fatty acids and monoglycerides. Orlistat, an FDA-approved drug, achieves a 30% reduction in body fat through irreversible covalent inhibition of PL. However, the gastrointestinal side effects limit its long-term use. To address these issues, we explored inhibition using natural compounds from Triphala (TRI), a renowned Ayurvedic formulation comprising three plants - Emblica officinalis (EO), Terminalia bellirica (TB), and Terminalia chebula (TC). This study investigated PL inhibition by an 80% hydro-ethanolic extract of individual herbs (EO, TB, TC) as well as, Triphala (TRI) and its fractions and identified key bioactive compounds - Ellagic acid, Chebulic acid and Corilagin via LC-MS/MS. Qualitative and quantitative phytochemical analyses revealed that TF1 is rich in phenols and tannins and exhibited significant PL inhibition compared to individual herb extracts. Additionally, Ellagic acid, Chebulic acid and Corilagin of TF1 demonstrated notable PL-inhibition, with IC
Indexed as
Identifiers
39946060What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.